Page 52 - ITPS-8-2

INNOSC Theranostics

and Pharmacological Sciences

REVIEW ARTICLE
Vericiguat for heart failure with reduced ejection

fraction (HFrEF): A review of its potential benefits
in Pakistan

Maria Qadri 1 , Komal Zulfiqar 2 , Daniah Rizwan 3 ,
5
Sulafa Rasheed Ahmed Ali 4 , Malik Olatunde Oduoye * ,
3
6
Ummsalamah Adenike Musa , Ahmad Sameed Akram , Awais Habib ,
3
Atif Hussain Sarwar , and Chinazom Judith Ejim 8
7
1 Department of Medicine, Jinnah Sindh Medical University, Karachi Pakistan
2 Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan
3 Department of Medicine, King Edward Medical University, Lahore, Pakistan
4 Department of Microbiology, Elfarabi College for Science and Technology, Khartoum, Sudan
5 Department of Research, The Medical Research Circle, Goma, Democratic Republic of Congo
6 Department of Medicine and Surgery, Yusuf Maitama Sule University, Kano, Kano State, Nigeria
7 Department of Medicine, Gujranwala Medical College, Gujranwala, Pakistan
8 Department of Medicine and Surgery, University of Nigeria, Nsukka, Nigeria

*Corresponding author:
Malik Olatunde Oduoye
(malikolatunde36@gmail.com) Abstract
Citation: Qadri M, Zulfiqar K, Heart failure (HF) is categorized by left ventricular ejection fraction (LVEF) into three
Rizwan D, et al. Vericiguat for heart
failure with reduced ejection fraction groups. HF with reduced ejection fraction (HFrEF) is one of these groups characterized
(HFrEF): A review of its potential by the heart’s inability to pump sufficient blood to meet the body’s needs, resulting
benefits in Pakistan. INNOSC from the left ventricle’s impaired ability to contract effectively. The Canadian
Theranostics and Pharmacological
Sciences. 2025;8(2):46-54. Cardiovascular Society (CCS) guidelines recommend vericiguat for hospitalized
doi: 10.36922/itps.3756 patients experiencing worsening symptoms of HFrEF. This article reviews vericiguat’s
efficacy and potential benefits in Pakistani patients with HFrEF. A literature search
Received: May 24, 2024
from 2013 to 2024 was conducted using PubMed, ScienceDirect, and Google
1st revised: September 26, 2024 Scholar, employing keywords such as guidelines, heart failure, Pakistan, and reduced
2nd revised: November 3, 2024 ejection fraction. Soluble guanylate cyclase (sGC) stimulators, like vericiguat, have
shown benefits in patients with left ventricular hypertrophy and fibrosis by reducing
3rd revised: November 26, 2024
afterload through vasodilation. Vericiguat (2.5 – 10 mg taken orally once daily) shows
Accepted: November 27, 2024 promise in reducing cardiovascular mortality and hospitalization in adults with LVEF
Published online: January 20, ≤45%. Vericiguat may alleviate Pakistan’s growing cardiovascular disease burden.
2025 Expedited access to this innovative therapy can be achieved through collaborative
Copyright: © 2025 This efforts among policymakers, healthcare authorities, and international research
is an Open-Access article centers, potentially reducing hospitalization rates in Pakistani HFrEF patients.
distributed under the terms
of the Creative Commons
AttributionNoncommercial License, Keywords: Vericiguat; Heart failure with reduced ejection fraction; Pakistan; Soluble
permitting all non-commercial use,
distribution, and reproduction in any guanylate cyclase stimulator; Cardiovascular disease
medium, provided the original work
is properly cited.
Publisher’s Note: AccScience
Publishing remains neutral with 1. Introduction
regard to jurisdictional claims in
published maps and institutional Heart failure (HF) is a multifaceted clinical condition characterized by dyspnea or
affiliations exertional limitation due to impaired ventricular filling, impaired blood ejection, or a

Volume 8 Issue 2 (2025) 46 doi: 10.36922/itps.3756